Gilead Sciences, Inc., a leading biopharmaceutical company headquartered in the United States, has been at the forefront of innovative healthcare since its founding in 1987. With a strong presence in regions such as Europe and Asia, Gilead focuses on the research, development, and commercialisation of antiviral drugs, particularly for HIV, hepatitis B, hepatitis C, and influenza. The company is renowned for its groundbreaking therapies, including Biktarvy and Harvoni, which have transformed the treatment landscape for chronic viral infections. Gilead's commitment to advancing medicine is underscored by its significant achievements, including multiple FDA approvals and a robust pipeline of investigational therapies. As a key player in the biopharmaceutical industry, Gilead Sciences continues to shape the future of healthcare through its dedication to scientific innovation and patient care.
How does Gilead Sciences's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Mean score of companies in the Research Services industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Gilead Sciences's score of 58 is higher than 99% of the industry. This can give you a sense of how well the company is doing compared to its peers.
In 2023, Gilead Sciences reported total greenhouse gas emissions of approximately 1,179,798,000 kg CO2e, with emissions distributed across various scopes: 56,096,000 kg CO2e (Scope 1), 22,339,000 kg CO2e (Scope 2), and 1,121,798,000 kg CO2e (Scope 3). The company has set ambitious targets to reduce its carbon footprint, committing to a 46% reduction in absolute Scope 1 and 2 emissions by 2030, using 2019 as the baseline year. Additionally, Gilead aims to decrease its absolute Scope 3 emissions by 15% over the same timeframe. In 2022, Gilead's emissions were reported as 1,202,703,000 kg CO2e, with Scope 1 emissions at 55,919,000 kg CO2e, Scope 2 at 40,000 kg CO2e, and Scope 3 at 1,202,703,000 kg CO2e. This indicates a significant reliance on Scope 3 emissions, which encompass indirect emissions from the supply chain and product lifecycle. Gilead's climate commitments include achieving carbon net-zero operational GHG emissions by 2030 for both Scope 1 and Scope 2 emissions. The company is actively working towards these targets, aligning its strategies with industry standards for climate action.
Access structured emissions data, company-specific emission factors, and source documents
2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | |
---|---|---|---|---|---|---|---|---|
Scope 1 | 44,754,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 |
Scope 2 | 29,127,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 |
Scope 3 | 32,003,000 | 00,000,000 | 00,000,000 | 0,000,000,000 | 0,000,000,000 | 0,000,000,000 | 0,000,000,000 | 0,000,000,000 |
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Gilead Sciences is participating in some of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.